Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
October 4, 2022
EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
TO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS
-
September 28, 2022
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
-
September 26, 2022
Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange
(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act)
-
September 26, 2022
METOJECT® SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS
-
September 21, 2022
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER’S DAY, SEPTEMBER 21
“LEARNING HELPS US TO BE KIND” LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP
-
September 12, 2022
Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
-
September 12, 2022
Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022
Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies
-
September 6, 2022
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combination’s Potential Across Difficult-to-Treat Cancers
Post-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulin’s Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisai’s Commitment to Advancing Understanding of Our Medicines
-
August 30, 2022
SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION
-
August 24, 2022
EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS
-
August 12, 2022
HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH
-
August 9, 2022
EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE
-
August 4, 2022
EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
-
August 3, 2022
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
-
July 26, 2022
EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 26, 2022
EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
-
July 25, 2022
AΒ-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE
-
July 15, 2022
REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS <effective as of July 15, 2022>
-
July 6, 2022
THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI’S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
-
June 29, 2022
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
-
June 28, 2022
E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF “IMPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING”
-
June 24, 2022
EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP “KIGALI DECLARATION” FOR ELIMINATING NEGLECTED TROPICAL DISEASES
CEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES
-
June 22, 2022
EISAI’S “NOUKNOW®”, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
-
June 22, 2022
EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling
-
June 8, 2022
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023
-
June 6, 2022
EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING
Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)
Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090)
-
June 3, 2022
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
-
May 30, 2022
Announcement of a Summary Share Exchange (kan’i kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary
-
May 27, 2022
EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022
Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai’s Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients
Presentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma
-
May 27, 2022
MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS
-
May 20, 2022
“MOVICOL® HD” Launched
A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan
-
May 13, 2022
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System
-
May 13, 2022
Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System
-
May 13, 2022
Notification Regarding Partial Amendment to the Articles of Incorporation
-
May 13, 2022
CHANGES OF CORPORATE OFFICERS
-
May 10, 2022
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
-
May 10, 2022
EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN
-
May 3, 2022
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022
-
April 27, 2022
Discontinuance (abolition) of the Policy for Protection of the Company’s Corporate Value and Common Interests of Shareholders
-
April 27, 2022
LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY
-
April 8, 2022
EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES’ NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER’S DISEASE
-
April 1, 2022
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
-
March 28, 2022
Announcement about an approval for additional indication of Jyseleca®, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies
Approval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis
-
March 22, 2022
Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer’s Disease
The Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022)
-
March 22, 2022
LATEST FINDINGS ON LECANEMAB – CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS – PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
-
March 15, 2022
ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER‘S DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN
-
March 15, 2022
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
-
March 11, 2022
EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD™ 2022 ANNUAL MEETING
-
March 9, 2022
EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500)
-
March 7, 2022
LENVIMA®（LENVATINIB）IN COMBINATION WITH KEYTRUDA®（PEMBROLIZUMAB）APPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
-
March 4, 2022
EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB
-
February 25, 2022
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Results From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for Sunitinib
LENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer
-
February 10, 2022
EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES’ PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER’S DISEASE
-
February 1, 2022
EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR® 2021
-
January 31, 2022
LENVIMA®（LENVATINIB）IN COMBINATION WITH KEYTRUDA®（PEMBROLIZUMAB）APPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
-
January 28, 2022
EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES
10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP “LONDON DECLARATION”
-
January 28, 2022
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
-
January 20, 2022
Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
-
January 19, 2022
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 19, 2022
FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI’S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU
EISAI’S ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY
-
January 17, 2022
EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM
-
January 13, 2022
Eisai’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
January 13, 2022
EISAI TO LAUNCH DIGITAL TOOL “CogMate™” IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH)
-
January 6, 2022
EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR
-
December 24, 2021
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
First Approval in Japan for the LENVIMA Plus KEYTRUDA Combination
-
December 24, 2021
INVESTIGATIONAL ALZHEIMER’S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION
-
December 22, 2021
Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
-
December 20, 2021
BIOGEN ANNOUNCES REDUCED PRICE FOR ADUHELM® TO IMPROVE ACCESS FOR PATIENTS WITH EARLY ALZHEIMER’S DISEASE IN THE UNITED STATES
-
December 20, 2021
EISAI ENTERS INTO COMMERCIALIZATION AND DISTRIBUTION AGREEMENT WITH GILEAD FOR JAK INHIBITOR FILGOTINIB IN ASIA
-
December 17, 2021
Update on Regulatory Submission for Aducanumab in the European Union
Biogen to seek re-examination following CHMP negative opinion for aducanumab
-
December 16, 2021
Update on the Phase 4 Confirmatory Study of ADUHELM®
-
December 6, 2021
EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 44TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
-
November 30, 2021
EISAI AND FCNT ENTER INTO BUSINESS ALLIANCE AIMING TO SUPPORT PEOPLE LIVING WITH DEMENTIA AND TO PREVENT DEMENTIA
Developing solutions such as smartphones equipped with the brain health check tool “NouKNOW®”
-
November 30, 2021
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND E2730 AT THE 75TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
-
November 29, 2021
European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
First Combination of Tyrosine Kinase Inhibitor with Immunotherapy Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation
Approval Based on Study 309/KEYNOTE-775 Results Demonstrating Statistically Significant Improvements in Overall Survival and Progression-Free Survival Compared With Chemotherapy
-
November 29, 2021
European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Approval Based on Results From CLEAR/KEYNOTE-581 Trial Demonstrating LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for Sunitinib
-
November 19, 2021
EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2021 FOR EIGHTH TIME
-
November 18, 2021
EISAI RECEIVES THE “MOST LIKED!” IR AWARD AT THE 2021 IR AWARD
-
November 17, 2021
Update on Regulatory Review of Aducanumab in the European Union
-
November 12, 2021
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
-
November 12, 2021
EISAI PRESENTS NEW ANALYSIS OF LECANEMAB CLINICAL EFFICACY RESULTS FROM PHASE 2B STUDY AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
Consistency of Efficacy Assessments Evaluated Across Various Statistical Methods
-
November 12, 2021
INTRODUCTION OF FIRST-OF-A-KIND PLASMA-BASED BIOMARKER SCREENING TO FACILITATE IDENTIFICATION OF SUBJECTS FOR PHASE 3 AHEAD 3-45 TRIAL PRESENTED AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
-
November 11, 2021
EISAI PRESENTS LATE-BREAKER UPDATES ON LECANEMAB CLINICAL, BIOMARKER AND SAFETY DATA FROM PHASE 2B STUDY CORE AND OPEN-LABEL EXTENSION ACROSS FIVE YEARS AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
-
November 9, 2021
DIAN-TU SELECTS LECANEMAB AS BACKGROUND ANTI-AMYLOID THERAPY IN CLINICAL TRIAL EVALUATING INVESTIGATIONAL THERAPY TARGETING TAU FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE
Eisai’s anti-microtubule binding region (MTBR) tau antibody E2814 previously selected as the first investigational therapy among anti-tau drugs for the DIAN-TU Tau Next Generation trial
-
November 4, 2021
Eisai and Digital Garage, Inc. Jointly Launch “Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)”, a Collaborative Cultivation Program with Dementia-related Startups
-
November 4, 2021
EISAI PRESENTS NEW DATA ON THE RELATIONSHIP BETWEEN CLINICAL, BIOMARKER AND SAFETY OUTCOMES FROM THE LECANEMAB PHASE 2B STUDY FOR EARLY ALZHEIMER’S DISEASE IN LATE-BREAKERS AND PIPELINE UPDATES AT THE 14TH CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
-
November 1, 2021
The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
-
October 18, 2021
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Two Different Types of Cancer
Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Benefit Compared to Sunitinib in CLEAR/KEYNOTE-581 Trial
Positive Opinion Granted for Advanced Endometrial Carcinoma Based on Significant OS and PFS Benefit Compared to Chemotherapy in Study 309/KEYNOTE-775 Trial
-
September 28, 2021
EISAI INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB (BAN2401) FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
LECANEMAB IS AN ANTI-AMYLOID BETA (Aβ) PROTOFIBRIL ANTIBODY
-
September 27, 2021
Fully Human Anti-TNFα Monoclonal Antibody HUMIRA® Obtains Additional Approval for High-Dose Regimen of Ulcerative Colitis in Adult Patients and for New Regimen in Pediatric Patients
-
September 14, 2021
EISAI TO JOIN THE GLOBAL ENVIRONMENTAL INITIATIVE “RE100”
-
September 14, 2021
EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2021
-
September 13, 2021
AbbVie, Eisai, and EA Pharma Launch “Humira® Support Tool Ordering Service for Patients” - an Initiative to Improve Patients’ Adherence to Humira® Therapy -
-
August 31, 2021
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in Five ASEAN Countries
-
August 16, 2021
ANTICANCER AGENT “TAZVERIK® TABLETS 200mg” (TAZEMETOSTAT HYDROBROMIDE) LAUNCHED IN JAPAN FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA
-
August 12, 2021
FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
LENVIMA Plus KEYTRUDA Is Now Approved for Two Types of Cancer, Including Advanced RCC
Based on Phase 3 CLEAR/KEYNOTE-581 Trial, LENVIMA Plus KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib
-
August 5, 2021
EISAI RECEIVES AWARD FOR EXCELLENCE IN CORPORATE COMMUNICATIONS AT THE 37TH CORPORATE COMMUNICATIONS AWARDS
-
August 4, 2021
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2022
-
August 2, 2021
ANTI-EPILEPTIC DRUG FYCOMPA® APPROVED IN CHINA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES AND PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES
-
July 30, 2021
LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFFECTS OF LECANEMAB (BAN2401)
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC)
-
July 30, 2021
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
-
July 29, 2021
EISAI LISTED FOR 20TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 27, 2021
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
-
July 22, 2021
FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation
Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma
-
July 21, 2021
EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMER’S DISEASE AND DEMENTIA AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2021
-
July 19, 2021
EISAI LAUNCHES BILE ACID TRANSPORTER INHIBITOR GOOFICE® IN THAILAND
-
July 19, 2021
STATUS OF ADUHELM™ IN THE UNITED STATES
-
July 8, 2021
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia
-
June 30, 2021
EISAI LAUNCHES IN-HOUSE DEVELOPED ANTI-INSOMNIA DRUG DAYVIGO® (LEMBOREXANT) IN HONG KONG
FIRST LAUNCH FOR DAYVIGO IN ASIA OUTSIDE OF JAPAN
-
June 29, 2021
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
-
June 24, 2021
EISAI AND BIOGEN INC. ANNOUNCE U.S. FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR LECANEMAB (BAN2401), AN ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY FOR THE TREATMENT OF ALZHEIMER’S DISEASE
-
June 23, 2021
SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS
-
June 23, 2021
ANTICANCER AGENT “TAZVERIK® TABLETS 200mg” (TAZEMETOSTAT HYDROBROMIDE) APPROVED IN JAPAN FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA
-
June 18, 2021
CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY’S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
-
June 18, 2021
EISAI AND BRISTOL MYERS SQUIBB ENTER INTO GLOBAL STRATEGIC COLLABORATION FOR EISAI’S MORAb-202 ANTIBODY DRUG CONJUGATE
-
June 15, 2021
EISAI TO DIVEST RIGHTS FOR ZONEGRAN® IN EUROPE AND OTHER REGIONS TO ADVANZ PHARMA
-
June 9, 2021
EISAI RECEIVES SPECIAL PRIZE AT PLATINUM CAREER AWARD 2021
-
June 9, 2021
EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 35th ANNUAL SLEEP MEETING (SLEEP2021)
-
June 8, 2021
Biogen and Eisai launch initiatives to help patients with Alzheimer’s disease access ADUHELM™
-
June 8, 2021
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease
In clinical trials, ADUHELM reduced amyloid beta plaques by 59 to 71 percent at 18 months of treatment
-
June 7, 2021
New Data on LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL Scales
-
May 31, 2021
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
-
May 20, 2021
EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING
-
May 19, 2021
ANTICANCER AGENT “Remitoro® INTRAVENOUS DRIP INFUSION 300μg” (DENILEUKIN DIFTITOX (GENETICAL RECOMBINATION)) LAUNCHED IN JAPAN FOR PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA
-
May 14, 2021
EISAI AND NATIONAL CANCER CENTER COMMENCE JOINT RESEARCH AND DEVELOPMENT PROJECT “BASIC RESEARCH ON THE DRUG DISCOVERY AND DEVELOPMENT TO ACCELERATE DEVELOPMENT OF ANTICANCER DRUGS IN TREATMENT OF PATIENTS WITH RARE CANCERS AND REFRACTORY CANCERS”, USING PDX WITH HIGH PREDICTABILITY OF CLINICAL OUTCOMES, AND CANCER GENOME DATA
-
May 11, 2021
EISAI'S STATEMENT OF COMMITMENT FOR CARBON NEUTRALITY BY 2040
A medium- to long-term goals to achieve carbon neutrality
-
May 6, 2021
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials
-
April 28, 2021
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
Building Dementia Ecosystem
-
April 23, 2021
APPLICATION SUBMITTED FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA® IN COMBINATION WITH KEYTRUDA® AS A TREATMENT FOR ADVANCED UTERINE BODY CANCER IN JAPAN
-
April 23, 2021
GILEAD SCIENCES SUBMITS NEW DRUG APPLICATION IN JAPAN FOR FILGOTINIB FOR THE TREATMENT OF ULCERATIVE COLITIS WITH AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPIES
Application is Based on Phase 2b/3 SELECTION Study Data with Patients with Moderately to Severely Active Ulcerative Colitis
-
April 23, 2021
NOTICE REGARDING BIOGEN’S DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS IN BRAZIL, CANADA, AUSTRALIA, AND SWITZERLAND FOR ADUCANUMAB FOR ALZHEIMER’S DISEASE
-
April 20, 2021
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease Published in Peer-Reviewed Journal, Alzheimer’s Research and Therapy
Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment
-
April 14, 2021
EISAI TO PRESENT LATEST DATA ON NEUROLOGY PRODUCTS AND PIPELINES AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
-
April 12, 2021
AN ANIMATION FEATURING LYMPHATIC FILARIASIS ELIMINATION ACTIVITIES RECEIVES ANIMATION AWARD AT INTERNATIONAL SOCIETY FOR NEGLECTED TROPICAL DISEASES FESTIVAL 2021
-
March 31, 2021
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
-
March 31, 2021
APPLICATION SUBMITTED FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA® IN COMBINATION WITH KEYTRUDA® AS A TREATMENT FOR ADVANCED RENAL CELL CARCINOMA IN JAPAN
-
March 30, 2021
EUROPEAN MEDICINES AGENCY ACCEPTS THE MARKETING AUTHORISATION APPLICATIONS FOR TWO ADDITIONAL INDICATIONS OF ANTI CANCER AGENT LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB AS A TREATMENT FOR ADVANCED RENAL CELL CARCINOMA AND ADVANCED ENDOMETRIAL CARCINOMA
-
March 26, 2021
DISCOVERY RESEARCH ON AMPA-TYPE GLUTAMATE RECEPTOR ANTAGONIST PERAMPANEL HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2021
-
March 23, 2021
LENVIMA®（LENVATINIB） APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE THYMIC CARCINOMA IN JAPAN
-
March 23, 2021
ANTICANCER AGENT “Remitoro® INTRAVENOUS DRIP INFUSION 300μg”(DENILEUKIN DIFTITOX (GENETIC RECOMBINANT)) APPROVED IN JAPAN FOR PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA
-
March 22, 2021
EISAI BEGINS CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
-
March 22, 2021
EISAI AWARDED THE NEW DIVERSITY MANAGEMENT SELECTION 100
-
March 19, 2021
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study
LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Death by 38%, With a Median Overall Survival of 18.3 Months Versus 11.4 Months With Chemotherapy Regardless of Mismatch Repair Status
First Results From Pivotal Study 309/KEYNOTE-775 Trial Presented at Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer
-
March 17, 2021
DZNE and EISAI ENTER INTO RESEARCH COLLABORATION AGREEMENT AIMING FOR NOVEL DRUG DISCOVERY FOR NEURODEGENERATIVE DISORDERS
-
March 16, 2021
ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 IS SELECTED ON CLINICAL STUDY FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE BY DIAN-TU
-
March 12, 2021
MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO ANTI-CANCER AGENT LENVIMA® (LENVATINIB) WITH PROSPECTIVE INDICATION FOR UTERINE BODY CANCER
-
March 5, 2021
EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMER’S DISEASE AND DEMENTIA AT THE 15TH INTERNATIONAL CONFERENCE ON ALZHEIMER’S AND PARKINSON’S DISEASE
-
March 4, 2021
EISAI CERTIFIED IN 2021 AS OUTSTANDING HEALTH AND PRODUCTIVITY MANAGEMENT ORGANIZATION (WHITE 500)
-
March 4, 2021
EISAI TO SUPPORT CONSTRUCTION OF SCREENING FRAMEWORK FOR THE NOVEL CORONAVIRUS INFECTION IN KENYA
-
March 2, 2021
NEW DRUG APPROVAL FOR IN-HOUSE DEVELOPED ANTI-INSOMNIA DRUG DAYVIGO® (LEMBOREXANT) IN HONG KONG
FIRST DRUG APPROVAL FOR DAYVIGO IN ASIA OUTSIDE OF JAPAN
-
February 22, 2021
MHLW GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO NOVEL FIBROBLAST GROWTH FACTOR (FGF) RECEPTOR SELECTIVE TYROSINE KINASE INHIBITOR E7090 WITH PROSPECTIVE INDICATION FOR UNRESECTABLE BILIARY TRACT CANCER WITH FGFR2 GENE FUSION
-
February 22, 2021
EISAI RECEIVES CORPORATE PHILANTHROPY AWARD FOR ITS EFFORTS TO REALIZE human health care (hhc) PHILOSOPHY
-
February 15, 2021
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
LENVIMA Plus KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib
LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib
First Results From Pivotal CLEAR Study (Study 307/KEYNOTE-581) Presented at 2021 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine
-
February 3, 2021
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2021
-
February 1, 2021
EISAI TO LAUNCH PARKINSON’S DISEASE TREATMENT EQUFINA® IN SOUTH KOREA
-
January 29, 2021
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021
-
January 25, 2021
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE FIFTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 12, 2021
EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2021 GASTROINTESTINAL CANCERS SYMPOSIUM
